Prostate cancer diagnosis-to-treatment time longer for African-Americans

This article originally appeared here.
Racial Disparity Exists in Time to Treat Prostate Cancer
Racial Disparity Exists in Time to Treat Prostate Cancer

(HealthDay News) -- African-American (AA) patients have longer waits from diagnosis of prostate cancer to treatment, compared with Caucasian patients, according to a study published online May 28 in Cancer.

William A. Stokes, from the University of North Carolina at Chapel Hill, and colleagues used data from the Surveillance, Epidemiologic and End Results-Medicare linked database to analyze potential differences in time to treat 2,506 AA and 21,454 Caucasian patients diagnosed with localized prostate cancer between 2004 and 2007. All patients were treated within 12 months.

The researchers found that, among all risk groups, the time from diagnosis to definitive (prostatectomy and radiation) treatment was longer for AA patients. This difference was most pronounced in high-risk cancer (96 versus 105 days; P < 0.001). Racial differences persisted for "any" and "definitive" treatment in multivariate analysis (β = 7.3 and 7.6, respectively). In high-risk disease compared with low-risk disease, and in more recent years, the delay to definitive treatment was longer.

"AA prostate cancer patients experienced longer time from diagnosis to treatment than Caucasian patients," the authors write. "AA patients appear to experience disparities across all aspects of this disease process, and together these factors in receipt of care plausibly contribute to the observed differences in rates of recurrence and mortality among AA and Caucasian prostate cancer patients."

Full Text (subscription or payment may be required)

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs